myelin

AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8

Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the VISIONARY-MS clinical trial. The findings continue to support Clene’s plans to…

Exposure to household chemicals harms myelin-making cells

Two types of chemicals in household disinfectants and furniture can disrupt the development of oligodendrocytes, the brain cells chiefly responsible for making myelin, a new study shows. The finding suggests that exposure to these chemicals may be a risk factor for disorders related to myelin such as…

Neurostimulator to repair myelin in RRMS named breakthrough device

The U.S. Food and Drug Administration has designated SetPoint Medicalā€™s neurostimulator a breakthrough device for the treatment of relapsing-remitting multiple sclerosis (RRMS). This designation is intended to accelerate the development of devices intending to more effectively treat or diagnose life-threatening or chronically debilitating diseases than standard approaches.

Myelin Provides Metabolic Support to Inhibitory Brain Cells: Study

Myelin, the fatty-rich material surrounding nerve fibers that’s progressively damaged in multiple sclerosis (MS), provides metabolic support to a type of nerve cell in the brain that controls the activity of other nerve cells, a study discovered. Researchers showed mitochondria, the cellā€™s energy producers, are specifically clustered in…

ProTEct-MS Trial Data Reinforce Previous Temelimab Studies

Higher doses of temelimab were generally safe and resulted in beneficial trends on key neurodegeneration markers in adults with relapsing forms of multiple sclerosis (MS) who already were on rituximab treatment, according to top-line data from the ProTEct-MS Phase 2 clinical trial. While the studyā€™s small size…

Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses

A Phase 1 clinical trial investigating the safety and tolerability ofĀ Anokion‘s ANK-700 in people withĀ relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening of the study’s second part follows positive safety signs in patients given the one of two doses of…

Cancer Researchers’ Discovery May Benefit MS Studies

In an unexpected discovery, scientists working to understand the biological underpinnings of brain tumors found that increasing the activity of a protein receptor called PDGFRA reduces the production of myelin ā€” the fatty coating that is lost in multiple sclerosis (MS) ā€” in the nervous system. “We saw that…

Signaling Protein Seen to Help Promote Myelin-making Cells

A signaling protein called fractalkine helps to regulate the development of oligodendrocytes, cells of the nervous system responsible for making myelin ā€” the protecting coating of nerve cell fibers that is damaged and lost inĀ multiple sclerosis (MS). This finding was in the study, “Fractalkine signaling regulates…

Anti-CD20 Antibodies Reduce Myelin Loss in MS Rats

Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of multiple sclerosis (MS), a new study reports. The findings imply that B-cells ā€” the immune cells that are killed by anti-CD20 antibodies ā€” play a central role in the…

Destroying Myelin-damaging Immune Cells May Be New Therapy

Vesicles containing the chemotherapeutic agent doxorubicin can be used to destroy the aberrant, myelin-damaging immune cells that contribute to multiple sclerosis (MS), suppressing the progression of the neurodegenerative disorder, according to recent research findings using a mouse model. If further validated, this technique could provide physicians with a new…

#ACTRIMS2021 – Young Brain Fluid (CSF) Rejuvenates Memory in Mice

Editorā€™s note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25-27. GoĀ hereĀ to see all the latest stories from the conference. Factors in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord change with age and can affect…

Enrollment Complete in Phase 2 Trial Testing Temelimab

GeNeuroĀ has completed patient enrollment in its ProTEct-MS Phase 2 clinical trial evaluating temelimab as a treatment for multiple sclerosis (MS), the company announced. The study (NCT04480307), taking place at the Karolinska Institutetā€™s Academic Specialist Center (ASC) in Stockholm, Sweden, has enrolled 42 people with relapsing MS whose…